Summary: Pfizer has discontinued development of its mini-dystrophin (micro-dystrophin) gene therapy, fordadistrogene movaparvovec, after failing to meet primary endpoints in Phase 3 clinical trials.
Summary: A startup biotechnology company developing brain disease therapeutics has secured an additional $225 million from a syndicate of prominent healthcare investors.
Summary: In the next three months, the FDA may approve new drugs including a competitor to Pfizer’s popular heart disease treatment, a controversial lung cancer therapy, and a new addition to Vertex’s strong cystic fibrosis portfolio.
Summary: Scientists have developed an effective method for treating injury patients, successfully cultivating arteries in the laboratory, which is already being effectively used in treating Ukrainian soldiers.
Summary: Ampista’s biotechnology platform utilizes synthetic biology to create customized molecules that meet specific performance requirements.
